Next Article in Journal
From Molecules to Medicines: The Role of AI-Driven Drug Discovery Against Alzheimer’s Disease and Other Neurological Disorders
Previous Article in Journal
Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 18
Issue 7
10.3390/ph18071040
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Pharmaceuticals 2025, 18(1), 43.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Liu et al. Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy. Pharmaceuticals 2025, 18, 43

by
Pei-Pei Liu
1,†,
Xin-Yue Yu
2,†,
Qing-Qing Pan
3,
Jia-Jun Ren
3,
Yu-Xuan Han
1,
Kai Zhang
1,
Yan Wang
4,
Yin Huang
2,3,* and
Tao Ban
1,5,6,*
1
Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China
2
Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 210009, China
3
Department of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
4
Department of Critical Care Medicine, Nanjing Drum Tower Hospital, Clinical College, Nanjing Medical University, Nanjing 210008, China
5
State Key Laboratory of Frigid Zone Cardiovascular Diseases, Ministry of Science and Technology, Harbin Medical University, Harbin 150081, China
6
Key Laboratory of Cardiovascular Research, Ministry of Education, Harbin Medical University, Harbin 150081, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2025, 18(7), 1040; https://doi.org/10.3390/ph18071040
Submission received: 11 June 2025 / Accepted: 27 June 2025 / Published: 14 July 2025
Browse Figures
Versions Notes

Error in Figure

In the original publication [1], there were two mistakes in Figures 7 and 8 as published. Figure 7G included an incorrect image due to file misplacement. Figure 8G incorrectly displayed the dataset intended for Figure 8B during the data import process. The corrected Figure 7 and Figure 8 appear below. The authors state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Liu, P.-P.; Yu, X.-Y.; Pan, Q.-Q.; Ren, J.-J.; Han, Y.-X.; Zhang, K.; Wang, Y.; Huang, Y.; Ban, T. Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy. Pharmaceuticals 2025, 18, 43. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 18 01040 g007
Figure 7. Acetaminophen (APAP) and pyridoxal phosphate (PLP) protect against cardiac injury in septic cardiomyopathy (SCM) mice. (A) Schematic of SCM mouse model and intervention; (B) heart weight/tibia length ratio (heart weight/TL) in each group (CON, n = 6; SCM, n = 6; SCM+APAP_L, n = 9; SCM+APAP_H, n = 9; SCM+PLP_L, n = 9; SCM+PLP_H, n = 9); (C) representative conventional echocardiography images; (D) echocardiographic analysis of mouse heart function (EF: ejection fraction; FS: fractional shortening); (E) serum levels of brain natriuretic peptide (BNP) and cardiac troponin I (cTn-I); (F) histological examination of mouse hearts with hematoxylin–eosin (H&E) staining (n = 3) (blue arrows: inflammatory cell infiltration); (G,H) the immunohistochemical staining of CD45 (G) and CD68 (H) in mouse hearts (red arrows: CD45-positive cells, green arrows: CD68-positive cells). One-way ANOVA, * p < 0.05, *** p < 0.001, **** p < 0.0001, ns: no significant difference.
Figure 7. Acetaminophen (APAP) and pyridoxal phosphate (PLP) protect against cardiac injury in septic cardiomyopathy (SCM) mice. (A) Schematic of SCM mouse model and intervention; (B) heart weight/tibia length ratio (heart weight/TL) in each group (CON, n = 6; SCM, n = 6; SCM+APAP_L, n = 9; SCM+APAP_H, n = 9; SCM+PLP_L, n = 9; SCM+PLP_H, n = 9); (C) representative conventional echocardiography images; (D) echocardiographic analysis of mouse heart function (EF: ejection fraction; FS: fractional shortening); (E) serum levels of brain natriuretic peptide (BNP) and cardiac troponin I (cTn-I); (F) histological examination of mouse hearts with hematoxylin–eosin (H&E) staining (n = 3) (blue arrows: inflammatory cell infiltration); (G,H) the immunohistochemical staining of CD45 (G) and CD68 (H) in mouse hearts (red arrows: CD45-positive cells, green arrows: CD68-positive cells). One-way ANOVA, * p < 0.05, *** p < 0.001, **** p < 0.0001, ns: no significant difference.
Pharmaceuticals 18 01040 g007
Pharmaceuticals 18 01040 g008
Figure 8. Acetaminophen (APAP) and pyridoxal phosphate (PLP) protect the heart against sepsis by regulating inflammation-related pathways and amino acid metabolism pathways, respectively. (A) The workflow of cell experiments. (B,C) Cell viability (B) and lactate dehydrogenase (LDH) activity (C) of H9c2 cells following vehicle, conditioned-medium (CM), and APAP treatment (n = 6). (D) Heatmap of normalized expression of genes involved in apoptosis (Bax), cardiac injury (Nppa), and inflammation (Tnfα, Il-1b, Il-6, and Nfkb2) (n = 6). (E) The highlighted subnetwork shows the inferred mechanism of action for APAP’s protective effect in septic cardiomyopathy (SCM). (F) Gene expression levels of key targets of APAP in the treatment of SCM (n = 6), CM vs. control: **** p < 0.0001, APAP vs. CM: #### p < 0.0001. (G,H) Cell viability (G) and LDH activity (H) of H9c2 cells following vehicle, CM, and PLP treatment (n = 6). (I) Principal component analysis (PCA) scatter plot based on the expression of genes involved in apoptosis (Bax), cardiac injury (Nppa), and inflammation (Tnfα, Il-1b, Il-6, and Nfkb2) (n = 6). (J) Joint pathway analysis of PLP–SCM interaction network nodes. (K) Normalized concentrations of 18 amino acids in H9c2 (n = 3). One-way ANOVA, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 8. Acetaminophen (APAP) and pyridoxal phosphate (PLP) protect the heart against sepsis by regulating inflammation-related pathways and amino acid metabolism pathways, respectively. (A) The workflow of cell experiments. (B,C) Cell viability (B) and lactate dehydrogenase (LDH) activity (C) of H9c2 cells following vehicle, conditioned-medium (CM), and APAP treatment (n = 6). (D) Heatmap of normalized expression of genes involved in apoptosis (Bax), cardiac injury (Nppa), and inflammation (Tnfα, Il-1b, Il-6, and Nfkb2) (n = 6). (E) The highlighted subnetwork shows the inferred mechanism of action for APAP’s protective effect in septic cardiomyopathy (SCM). (F) Gene expression levels of key targets of APAP in the treatment of SCM (n = 6), CM vs. control: **** p < 0.0001, APAP vs. CM: #### p < 0.0001. (G,H) Cell viability (G) and LDH activity (H) of H9c2 cells following vehicle, CM, and PLP treatment (n = 6). (I) Principal component analysis (PCA) scatter plot based on the expression of genes involved in apoptosis (Bax), cardiac injury (Nppa), and inflammation (Tnfα, Il-1b, Il-6, and Nfkb2) (n = 6). (J) Joint pathway analysis of PLP–SCM interaction network nodes. (K) Normalized concentrations of 18 amino acids in H9c2 (n = 3). One-way ANOVA, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Pharmaceuticals 18 01040 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, P.-P.; Yu, X.-Y.; Pan, Q.-Q.; Ren, J.-J.; Han, Y.-X.; Zhang, K.; Wang, Y.; Huang, Y.; Ban, T. Correction: Liu et al. Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy. Pharmaceuticals 2025, 18, 43. Pharmaceuticals 2025, 18, 1040. https://doi.org/10.3390/ph18071040

AMA Style

Liu P-P, Yu X-Y, Pan Q-Q, Ren J-J, Han Y-X, Zhang K, Wang Y, Huang Y, Ban T. Correction: Liu et al. Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy. Pharmaceuticals 2025, 18, 43. Pharmaceuticals. 2025; 18(7):1040. https://doi.org/10.3390/ph18071040

Chicago/Turabian Style

Liu, Pei-Pei, Xin-Yue Yu, Qing-Qing Pan, Jia-Jun Ren, Yu-Xuan Han, Kai Zhang, Yan Wang, Yin Huang, and Tao Ban. 2025. "Correction: Liu et al. Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy. Pharmaceuticals 2025, 18, 43" Pharmaceuticals 18, no. 7: 1040. https://doi.org/10.3390/ph18071040

APA Style

Liu, P.-P., Yu, X.-Y., Pan, Q.-Q., Ren, J.-J., Han, Y.-X., Zhang, K., Wang, Y., Huang, Y., & Ban, T. (2025). Correction: Liu et al. Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy. Pharmaceuticals 2025, 18, 43. Pharmaceuticals, 18(7), 1040. https://doi.org/10.3390/ph18071040

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop